Chemical Biology Laboratory, Department of Sericulture, Raiganj University, North Dinajpur, West Bengal, 733134, India.
S-inova Biotech, Programa de Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande, Brazil; Centro de Análises Proteômicas e Bioquímicas, Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, Brazil; Instituto de Biociências (INBIO), Universidade Federal de Mato Grosso do Sul, Cidade Universitária, Campo Grande, Mato Grosso do Sul, Brazil.
Travel Med Infect Dis. 2023 Mar-Apr;52:102557. doi: 10.1016/j.tmaid.2023.102557. Epub 2023 Feb 20.
Patients with respiratory viral infections are more likely to develop co-infections leading to increased fatality. Mucormycosis is an epidemic amidst the COVID-19 pandemic that conveys a 'double threat' to the global health fraternity. Mucormycosis is caused by the Mucorales group of fungi and exhibits acute angioinvasion generally in immunocompromised patients. The most familiar foci of infections are sinuses (39%), lungs (24%), and skin tissues (19%) where the overall dissemination occurs in 23% of cases. The mortality rate in the case of disseminated mucormycosis is found to be 96%. Symptoms are mostly nonspecific and often resemble other common bacterial or fungal infections. Currently, COVID-19-associated mucormycosis (CAM) is being reported from a number of countries such as the USA, Turkey, France, Mexico, Iran, Austria, UK, Brazil, and Italy, while India is the hotspot for this deadly co-infection, accounting for approximately 28,252 cases up to June 8, 2021. It strikes patients within 12-18 days after COVID-19 recovery, and nearly 80% require surgery. Nevertheless, the mortality rate can reach 94% if the diagnosis is delayed or remains untreated. Sometimes COVID-19 is the sole predisposing factor for CAM. Therefore, this study may provide a comprehensive resource for clinicians and researchers dealing with fungal infections, intending to link the potential translational knowledge and prospective therapeutic challenges to counter this opportunistic pathogen.
患有呼吸道病毒感染的患者更容易发生合并感染，从而导致死亡率增加。在 COVID-19 大流行期间，毛霉菌病是一种流行疾病，对全球医学界构成“双重威胁”。毛霉菌病是由毛霉目真菌引起的，通常发生在免疫功能低下的患者中，表现为急性血管侵袭。最常见的感染部位是鼻窦（39%）、肺部（24%）和皮肤组织（19%），其中 23%的病例会发生全身播散。在弥散性毛霉菌病的情况下，死亡率为 96%。症状大多是非特异性的，常类似于其他常见的细菌或真菌感染。目前，美国、土耳其、法国、墨西哥、伊朗、奥地利、英国、巴西和意大利等国报告了 COVID-19 相关毛霉菌病（CAM），而印度是这种致命合并感染的热点地区，截至 2021 年 6 月 8 日，约有 28252 例。它在 COVID-19 康复后 12-18 天内袭击患者，近 80%的患者需要手术。然而，如果诊断延迟或未得到治疗，死亡率可能高达 94%。有时 COVID-19 是 CAM 的唯一诱发因素。因此，本研究可能为处理真菌感染的临床医生和研究人员提供全面的资源，旨在将潜在的转化知识和前瞻性治疗挑战联系起来，以对抗这种机会性病原体。
